ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,836.22
0.16%
US Tech 100
20,263.60
-0.12%
Dow Jones
42,297.12
0.86%
Brent Oil
80.28
-0.42%
Bitcoin
94,347.02
-0.15%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Vivoryon Therapeut (VVY) Quote

Vivoryon Therapeut

Vivoryon Therapeut (VVY)

EU
2.00
0.01
(0.50%)
Closed January 13 11:30AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
2.00
Bid
1.924
Ask
2.02
Volume
57,810
1.93 Day's Range 2.005
0.41 52 Week Range 9.93
Market Cap
-
Previous Close
1.99
Open
2.00
Last Trade
133
@
2
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
186,850
Shares Outstanding
0.00
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
-3.62M
Net Profit
-28.34M

About Vivoryon Therapeut

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.vivoryon.com
Headquarters
Halle, Deu
Founded
-
Vivoryon Therapeut is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker VVY. The last closing price for Vivoryon Therapeut was 1.99 €. Over the last year, Vivoryon Therapeut shares have traded in a share price range of 0.41 € to 9.93 €.

Vivoryon Therapeut currently has 0 shares outstanding.

Ask ADVFN Intelligence (AI)

VVY Latest News

More News

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

December 09 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

December 04 2024
UK Regulatory

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

October 26 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

October 11 2024
UK Regulatory

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

October 01 2024
UK Regulatory

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

September 12 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

July 18 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Halle (Saale) / Munich, Germany, July 9, 2024 - Vivoryon Therapeutics N.V. (Euronext...

July 09 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.22-9.909909909912.222.241.931332992.04721546DE
40.031.522842639591.972.241.9121081002.03437528DE
12-0.39-16.31799163182.392.71.671868502.20259279DE
26-0.23-10.31390134532.232.9951.672334312.30462252DE
52-5.78-74.2930591267.789.930.415643581.98394633DE
156-15.982-88.877766655517.98219.560.412316093.7026339DE
260-3.2-61.53846153855.223.250.411778745.10238737DE

VVY - Frequently Asked Questions (FAQ)

What is the current Vivoryon Therapeut share price?
The current share price of Vivoryon Therapeut is 2.00 €
What is the 1 year trading range for Vivoryon Therapeut share price?
Vivoryon Therapeut has traded in the range of 0.41 € to 9.93 € during the past year
What is the reporting currency for Vivoryon Therapeut?
Vivoryon Therapeut reports financial results in EUR
What is the latest annual turnover for Vivoryon Therapeut?
The latest annual turnover of Vivoryon Therapeut is EUR -3.62M
What is the latest annual profit for Vivoryon Therapeut?
The latest annual profit of Vivoryon Therapeut is EUR -28.34M
What is the registered address of Vivoryon Therapeut?
The registered address for Vivoryon Therapeut is WEINBERGWEG 22, HALLE, 06120
What is the Vivoryon Therapeut website address?
The website address for Vivoryon Therapeut is www.vivoryon.com
Which industry sector does Vivoryon Therapeut operate in?
Vivoryon Therapeut operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HYPDSHipay Group DS
0.0024 €
(200.00%)
1.83k
ALCYBCybergun
0.0002 €
(100.00%)
16.61M
BNBSTonner Drones
0.0015 €
(50.00%)
100
ALLPLLepermislibre SA
0.60 €
(50.00%)
27.77k
ALVGVEOM Group
0.16 €
(22.14%)
87.97k
ALTHETheraclion
0.23 €
(-17.86%)
34.88k
MLPACPacte Novation
8.35 €
(-14.80%)
3
ALALOAcheterLouerFR
0.0958 €
(-12.91%)
121.44k
MLVIRVirtualware 2007 SA
7.40 €
(-11.90%)
150
MLBONBonyf NV
15.90 €
(-11.67%)
105
ATOAtos SE
0.0022 €
(10.00%)
2.22B
BCPBanco Comercial Portugues SA
0.4802 €
(0.00%)
49.83M
ALVERVergnet
0.0017 €
(-5.56%)
18.84M
ALCYBCybergun
0.0002 €
(100.00%)
16.61M
INGAING Groep NV
15.538 €
(3.17%)
14.34M

Discussion

View Full Feed
nilremerlin nilremerlin 4 minutes ago
50 dma still holding even at .61 above the 200 dma, the last 6 days of price dip consolidation still confirming the integrity of the Golden Cross.
VWAP 3.04 US, Down today.
Close $3.07 US, Down today.
Volume was slightly more than the
10-day average volume today.
$
HITI
flipper44 flipper44 4 minutes ago
Thank You TVA! Excellent Due Dilugence follow up. Thank you!
NWBO
Huggy Bear Huggy Bear 4 minutes ago
There was no huge bid support EOD. There was however a last two minute paint job to close even for the day.
HMBL
blackhawks blackhawks 4 minutes ago
Yeah, I noticed that. I'm sure there'll be a recap at the beginning of the new season. It was an edge of the seat page turner.
Seminole Red Seminole Red 4 minutes ago
yay
jimr1717 jimr1717 4 minutes ago
In 1979, Hutchison claimed to have discovered a number of unusual phenomena while trying to duplicate experiments done by Nikola Tesla. Such as disappearance of metals and fusion of materials together.

The article is nothing to do with science, it's all about assumptions and distorti
SINT
ElectricJester54 ElectricJester54 6 minutes ago
Today was actually the first day I sold a single share of any Cohen ticker and I used it to buy more of another Cohen ticker haha. Fidelity has my transferred money on lockdown since they won't let you buy stock that is below $3 per share now until the money is fully cleared in 4 to 6 days. So I sol
AZRH ZHUD
PioneerCorsair42 PioneerCorsair42 7 minutes ago
Ummm, I think the bashers are laughing!
SPZI
Hestheman47 Hestheman47 7 minutes ago
Why the huge fall?
AEXAY
CarlCarlMcB CarlCarlMcB 7 minutes ago
This is way over sold to be going in to a R/S ,  they should ask for 180 days !!!
SVMH
pos_stock_hoarder pos_stock_hoarder 8 minutes ago
A very lucky find considering that I live in NJ!
The_Free_Nebula The_Free_Nebula 8 minutes ago
The company still hanging out the proverbial thin thread...GLTA hanging on with them
KITL
Bill48 Bill48 9 minutes ago
I agree that 75/25 settlement only makes
sense too!! Thanks !
COOP
Tahoe2468 Tahoe2468 9 minutes ago
Still dumbfounded on volume even for a OTC stock 
KRTL
penguin007 penguin007 9 minutes ago
I think it's a good thing that our current sp is based on real value of what Co is today. I see other stocks making crazy spikes in sp, and it's all based on hype and promises of what Co might/could/should do some day? We know what we own as far as today, and that's why we're trading at sustained sp
ZHUD
Sogo Sogo 9 minutes ago
Gang, An enormous propaganda push is coming! It’s going to be a challenge to counteract it but we must try. If the “public input phase” ends up happening (seems there’s a small chance the new administration could do away with the scheduled “public input phase”), then we should absolutely expect the
FNMA
ElectricJester54 ElectricJester54 9 minutes ago
Well I am hoping they both run, but I should hopefully have my money cleared in Fidelity tomorrow and I will be right back to where I was in ZHUD. I just have a few good more cheap AZRH shares in my port instead. Plus I have way more ZHUD than AZRH cause I found out about ZHUD well before AZRH was e
AZRH ZHUD
ksquared ksquared 11 minutes ago
Homes are piling up on the market in Florida — there are 2 big reasons why
By Julie Gerstein Published Jan. 13, 2025, 2:45 p.m. ET

The rosy glow of the COVID-19 pandemic real estate market appears to be drying up in the Sunshine State of Florida.

The December 20
vlispxpert vlispxpert 11 minutes ago
But even better ones coming, got some ops trades coming too...stay tuned
4retire 4retire 12 minutes ago
Where did all of these malcontents come from? NVDA has been one of the greatest performing stocks for over 2-1/2 years now. They continually improve their product offerings for speed and power efficiency. They have many years head start on all competitors, even with competitors going at break nec
NVDA

Your Recent History

EU
VVY
Vivoryon Therapeut
NYSE
SSU
SIGNA Sports United NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads